Brand names: 6% Hetastarch In 0.9% Sodium Chloride
Plasma Volume Expander · Osmotic Activity
Route: Intravenous
FDA Black Box Warning
BOXED WARNING BOXED WARNING
Contraindications
4 CONTRAINDICATIONS Do not use hydroxyethyl starch (HES) products, including 6% Hetastarch in 0.9% Sodium Chloride Injection, in critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy (RRT). • Do not use HES products, including 6% Hetastarch in 0.9% Sodium Chloride Injection, in patients with severe liver disease • Do not use HES products, including 6% Hetastarch in 0.9% Sodium Chloride Injection, in patients with known hypersensitivity to hydroxyethyl starch • Do not use HES products, including 6% Hetastarch in 0.9% Sodium Chloride Injection, in clinical conditions where volume overload is a potential problem (such as, congestive heart failure or renal disease with anuria or oliguria not related to hypovolemia). • Do not use HES products, including 6% Hetastarch in 0.9% Sodium Chloride Injection, in patients with pre-existing coagulation or bleeding disorders
1 interaction on record
6% Hetastarch in 0.9% Sodium Chloride should be used with caution in patients anticoagulated with drugs that negatively influence coagulation system due to potential additive effects on bleeding risk.
Source: NLP:6% hetastarch in 0.9% sodium chloride